Follow the Devyser Diagnostics AB stock price and the full management transaction log of the company, a listed issuer based in Finland. Shares are listed on FI FI, under the authority of FIN-FSA. Operating in the Health Care sector, Devyser Diagnostics AB has recorded 14 reports. Market capitalisation: €1bn. The latest transaction was disclosed on 10 June 2026 (Other). Among the most active insiders: Mia Arnhult. All data is free.
14
Insider Decl.
0
Thresholds
€266,715
8 ops.
Buy Volume
·
0 ops.
Sell Volume
43Σ signal
Buys €266,715· Sells
Fundamental score
Ranked 19,475 of 25,899 companies
34.5
score / 100
Value
18
Quality
51
FCF yld-6.0%
Earn yld-0.8%
EV/EBITDA39.5x
ROE4.4%
Gross mgn81%
Net mgn-3.4%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
500 shares@ €10.47980.0003% mcap3.6% of flowAktieFI:A003M385-1
Ideal exit: 5 Dec 2025 (T+270)
14 of 14 declarations
About Devyser Diagnostics AB
Devyser Diagnostics AB is a company focused on developing molecular diagnostic tests. It specializes in solutions for the diagnosis of genetic diseases and cancers.